NASDAQ:GLYC

GlycoMimetics (GLYC) Stock Forecast, Price & News

$1.90

-0.02 (-1.04%)

(As of 06/2/2023 ET)

Compare

Today's Range: $1.85
▼
$1.96
50-Day Range: $1.21
▼
$2.08
52-Week Range: $0.51
▼
$4.16

Volume: 185,941 shs
Average Volume: 960,645 shs
Market Capitalization: $122.08 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $8.00

GlycoMimetics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 321.1% Upside
$8.00 Price Target
Short Interest: Healthy
2.05% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.55
Upright™ Environmental Score
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$67,995 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.74) to ($0.76) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

385th out of 983 stocks

Pharmaceutical Preparations Industry

183rd out of 486 stocks

3.5

Analyst's Opinion

Consensus Rating
GlycoMimetics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $8.00, GlycoMimetics has a forecasted upside of 321.1% from its current price of $1.90.
Amount of Analyst Coverage
GlycoMimetics has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
2.05% of the outstanding shares of GlycoMimetics have been sold short.
Short Interest Ratio / Days to Cover
GlycoMimetics has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in GlycoMimetics has recently decreased by 2.22%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
GlycoMimetics does not currently pay a dividend.
Dividend Growth
GlycoMimetics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
GlycoMimetics has received a 73.56% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Preclinical research services for physical health", "Clinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for GlycoMimetics is -0.55.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for GlycoMimetics this week, compared to 2 articles on an average week.
Search Interest
Only 7 people have searched for GLYC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added GlycoMimetics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, GlycoMimetics insiders have bought 842.41% more of their company's stock than they have sold. Specifically, they have bought $67,995.00 in company stock and sold $7,215.00 in company stock.
Percentage Held by Insiders
Only 8.00% of the stock of GlycoMimetics is held by insiders.
Percentage Held by Institutions
49.50% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for GlycoMimetics are expected to decrease in the coming year, from ($0.74) to ($0.76) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of GlycoMimetics is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of GlycoMimetics is -2.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
GlycoMimetics has a P/B Ratio of 1.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About GlycoMimetics (NASDAQ:GLYC) Stock

GlycoMimetics, Inc. engages in the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. It develops proprietary glycomimetics that inhibit disease related functions of carbohydrates. The company was founded by Rachel K. King and John L. Magnani on April 4, 2003 and is headquartered in Rockville, MD.

Receive GLYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GlycoMimetics and its competitors with MarketBeat's FREE daily newsletter.

GLYC Stock News Headlines

May 31, 2023 | finance.yahoo.com

GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference

May 30, 2023 | msn.com

GlycoMimetics: Insider Buying Continues, And Chart Looks Healthy

June 3, 2023 | Stocks To Trade (Ad)

15 A.I. Trading Opportunities a Day

Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.

May 16, 2023 | finance.yahoo.com

retail investors who own 36% along with institutions invested in GlycoMimetics, Inc. (NASDAQ:GLYC) saw increase in their holdings value last week

May 13, 2023 | americanbankingnews.com

Insider Buying: GlycoMimetics, Inc. (NASDAQ:GLYC) Director Acquires 30,000 Shares of Stock

May 12, 2023 | seekingalpha.com

GlycoMimetics: An Asymmetric Opportunity That Could Change Hematology

May 11, 2023 | americanbankingnews.com

GlycoMimetics, Inc. (NASDAQ:GLYC) SVP Bruce S. Johnson Purchases 13,500 Shares

May 9, 2023 | americanbankingnews.com

HC Wainwright Analysts Lower Earnings Estimates for GlycoMimetics, Inc. (NASDAQ:GLYC)

June 3, 2023 | Stocks To Trade (Ad)

15 A.I. Trading Opportunities a Day

Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.

May 4, 2023 | finance.yahoo.com

Q1 2023 GlycoMimetics Inc Earnings Call

May 3, 2023 | finance.yahoo.com

GlycoMimetics Reports Highlights and Financial Results for First Quarter 2023

April 26, 2023 | finance.yahoo.com

GlycoMimetics to Report First Quarter 2023 Financial Results on May 3, 2023

April 19, 2023 | finance.yahoo.com

Possible turnaround for GlycoMimetics, Inc. (NASDAQ:GLYC) insiders, still down US$63k after a US$732k shopping spree

April 4, 2023 | americanbankingnews.com

GlycoMimetics, Inc. (NASDAQ:GLYC) Expected to Earn Q1 2023 Earnings of ($0.17) Per Share

April 4, 2023 | americanbankingnews.com

HC Wainwright Comments on GlycoMimetics, Inc.'s Q1 2023 Earnings (NASDAQ:GLYC)

April 2, 2023 | americanbankingnews.com

HC Wainwright Reaffirms Buy Rating for GlycoMimetics (NASDAQ:GLYC)

March 31, 2023 | finance.yahoo.com

GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2022 Earnings Call Transcript

March 28, 2023 | americanbankingnews.com

GlycoMimetics (GLYC) Scheduled to Post Quarterly Earnings on Wednesday

March 25, 2023 | americanbankingnews.com

GlycoMimetics (NASDAQ:GLYC) Lowered to "Sell" at StockNews.com

March 17, 2023 | finance.yahoo.com

GlycoMimetics, Inc. (GLYC) Interactive Stock Chart - Yahoo Finance

March 16, 2023 | finance.yahoo.com

GlycoMimetics to Report Fourth Quarter and 2022 Full Year Financial Results on March 29, 2023

March 5, 2023 | uk.finance.yahoo.com

GlycoMimetics, Inc. (GLYC) stock price, news, quote & history – Yahoo Finance

March 1, 2023 | finance.yahoo.com

GlycoMimetics to Participate in Upcoming Cowen 43rd Annual Health Care Conference

February 21, 2023 | marketwatch.com

Sickle Cell Anemia Therapeutics Market by Top Manufacturers, Growing Demand and Supply 2023-2028

February 15, 2023 | finance.yahoo.com

GlycoMimetics Announces Continuation of Phase 3 Study of E-selectin Antagonist Uproleselan in Relapsed/Refractory AML to Originally Planned Final Analysis Following Interim Analysis by Independent Data Monitoring Committee

January 22, 2023 | finance.yahoo.com

GlycoMimetics, Inc.'s (NASDAQ:GLYC) Shift From Loss To Profit

January 22, 2023 | finance.yahoo.com

This Small Pharma Company Could Develop Into a Nice Trade

See More Headlines

GLYC Price History

30 days | 90 days | 365 days | Advanced Chart

GLYC Company Calendar

Last Earnings: 3/29/2023
Today: 6/03/2023
Next Earnings (Estimated): 8/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GLYC
CUSIP: N/A
CIK: 1253689
Web: www.glycomimetics.com
Phone: (240) 243-1201
Fax: 301-738-2137
Employees: 52
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $8.00
High Stock Price Forecast: $8.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +321.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.77)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-46,690,000.00
Net Margins: N/A
Pretax Margin: -56,526.67%
Return on Equity: -81.16%
Return on Assets: -70.15%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 10.10
Quick Ratio: 10.10

Sales & Book Value

Annual Sales: $80,000.00
Price / Sales: 1,525.94
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.97 per share
Price / Book: 1.96

Miscellaneous

Outstanding Shares: 64,250,000
Free Float: 59,106,000
Market Cap: $122.08 million
Optionable: Optionable
Beta: 2.10

Key Executives

Harout Semerjian
President, Chief Executive Officer & Director

Brian M. Hahn
Chief Financial Officer & Senior Vice President

Deepak Tiwari
Vice President-Technical Operations

Edwin P. Rock
Chief Medical Officer & Senior Vice President

Bruce Johnson
Chief Commercial Officer & Senior Vice President

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GLYC Stock - Frequently Asked Questions

Should I buy or sell GlycoMimetics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" GLYC shares.
View GLYC analyst ratings or view top-rated stocks.
What is GlycoMimetics' stock price forecast for 2023?: 1 Wall Street research analysts have issued 1 year target prices for GlycoMimetics' stock. Their GLYC share price forecasts range from $8.00 to $8.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 321.1% from the stock's current price.
View analysts price targets for GLYC or view top-rated stocks among Wall Street analysts.
How have GLYC shares performed in 2023?: GlycoMimetics' stock was trading at $3.03 at the beginning of the year. Since then, GLYC shares have decreased by 37.3% and is now trading at $1.90.
View the best growth stocks for 2023 here.
When is GlycoMimetics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our GLYC earnings forecast.
How were GlycoMimetics' earnings last quarter?: GlycoMimetics, Inc. (NASDAQ:GLYC) released its quarterly earnings results on Wednesday, March, 29th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.02.
What other stocks do shareholders of GlycoMimetics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other GlycoMimetics investors own include Exelixis (EXEL), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), Cidara Therapeutics (cdtx), Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), Spectrum Pharmaceuticals (SPPI), Coherus BioSciences (CHRS), Verastem (VSTM) and Aldeyra Therapeutics (ALDX).

What is GlycoMimetics' stock symbol?: GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."
Who are GlycoMimetics' major shareholders?: GlycoMimetics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include AXA S.A. (2.50%), Acadian Asset Management LLC (2.18%), BlackRock Inc. (1.01%), Two Sigma Advisers LP (0.93%), Two Sigma Investments LP (0.58%) and Affinity Asset Advisors LLC (0.00%). Insiders that own company stock include Brian M Hahn, Bruce S Johnson, Bvf Partners L P/Il, Daniel M Junius, Edwin Rock, John L Magnani, Patricia S Andrews, Public Equities LP Invus and Scott D Sandell.
View institutional ownership trends.
How do I buy shares of GlycoMimetics?: Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is GlycoMimetics' stock price today?: One share of GLYC stock can currently be purchased for approximately $1.90.
How much money does GlycoMimetics make?: GlycoMimetics (NASDAQ:GLYC) has a market capitalization of $122.08 million and generates $80,000.00 in revenue each year. The biotechnology company earns $-46,690,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.
How can I contact GlycoMimetics?: GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The official website for the company is www.glycomimetics.com. The biotechnology company can be reached via phone at (240) 243-1201, via email at sannes@annesassociates.com, or via fax at 301-738-2137.

This page (NASDAQ:GLYC) was last updated on 6/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial